z-logo
open-access-imgOpen Access
Pathological findings in central nervous system demyelination associated with infliximab
Author(s) -
Alicja Kalinowska-Łyszczarz,
Mahboobeh Fereidan-Esfahani,
Yuxin Guo,
Claudia F. Lucchinetti,
W. Oliver Tobin
Publication year - 2019
Publication title -
multiple sclerosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.729
H-Index - 131
eISSN - 1477-0970
pISSN - 1352-4585
DOI - 10.1177/1352458519894710
Subject(s) - infliximab , medicine , multiple sclerosis , central nervous system , rheumatoid arthritis , pathological , pathology , demyelinating disorder , tumor necrosis factor alpha , immunology
Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here